Axsome Therapeutics Inc
AXSM
View Detailed Chart
182.550USD
+1.710+0.95%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
9.18BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+0.95%
5 Days
-0.92%
1 Month
+6.21%
6 Months
+76.79%
Year to Date
-0.05%
1 Year
+66.71%
View Detailed Chart
TradingKey Stock Score of Axsome Therapeutics Inc
Currency: USD Updated: 2026-02-06Key Insights
Axsome Therapeutics Inc's fundamentals are relatively healthy, with industry-average ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 40 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 213.05.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Axsome Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Axsome Therapeutics Inc Highlights
StrengthsRisks
Axsome Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for people living with central nervous system (CNS) conditions. The Company's commercial products include Auvelity, Sunosi and Symbravo. It is also advancing a diversified, late-stage pipeline of product candidates for serious neurological and psychiatric conditions, which include AXS-05, AXS-12, AXS-14 and AXS-17. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. Symbravo (meloxicam and rizatriptan, 20 mg/10mg tablets) is an oral, single-dose medicine approved for the acute treatment of migraine with or without aura in adults.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 670.81% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 385.69M.
Undervalued
The company’s latest PE is -39.08, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 38.50M shares, increasing 0.21% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 7.37K shares of this stock.
Analyst Rating
Based on
20
analysts
Buy
Current Rating
213.053
Target Price
+17.81%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Axsome Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Axsome Therapeutics Inc Info
Axsome Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for people living with central nervous system (CNS) conditions. The Company's commercial products include Auvelity, Sunosi and Symbravo. It is also advancing a diversified, late-stage pipeline of product candidates for serious neurological and psychiatric conditions, which include AXS-05, AXS-12, AXS-14 and AXS-17. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. Symbravo (meloxicam and rizatriptan, 20 mg/10mg tablets) is an oral, single-dose medicine approved for the acute treatment of migraine with or without aura in adults.
Ticker SymbolAXSM
CompanyAxsome Therapeutics Inc
CEOTabuteau (Herriot)
Websitehttps://www.axsome.com/
Related Instruments
+3.66%
+3.17%
+0.93%
+1.99%
+1.78%
+1.60%
-0.95%
+4.49%
+2.10%
+10.00%
+2.72%
+4.15%
+1.81%
+4.17%
+0.72%
+1.06%
+2.46%
0.00%
+0.53%
+0.56%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
68949.990
-1020.140 (-1.46%)
282.580
+22.390 (+8.61%)
2050.100
-1.630 (-0.08%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
